Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

Abstract:

:We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 targeting miR-26a, and EZH2 induces MYC via inhibition of the MYC targeting miR-494 to create positive feedback. Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo. These findings define a MYC-mediated miRNA repression mechanism, shed light on MYC lymphomagenesis mechanisms, and reveal promising therapeutic targets for aggressive B-cell malignancies.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Zhang X,Zhao X,Fiskus W,Lin J,Lwin T,Rao R,Zhang Y,Chan JC,Fu K,Marquez VE,Chen-Kiang S,Moscinski LC,Seto E,Dalton WS,Wright KL,Sotomayor E,Bhalla K,Tao J

doi

10.1016/j.ccr.2012.09.003

subject

Has Abstract

pub_date

2012-10-16 00:00:00

pages

506-523

issue

4

eissn

1535-6108

issn

1878-3686

journal_volume

22

pub_type

杂志文章
  • ATMIN is required for maintenance of genomic stability and suppression of B cell lymphoma.

    abstract::Defective V(D)J rearrangement of immunoglobulin heavy or light chain (IgH or IgL) or class switch recombination (CSR) can initiate chromosomal translocations. The DNA-damage kinase ATM is required for the suppression of chromosomal translocations but ATM regulation is incompletely understood. Here, we show that mice l...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2011.03.022

    authors: Loizou JI,Sancho R,Kanu N,Bolland DJ,Yang F,Rada C,Corcoran AE,Behrens A

    更新日期:2011-05-17 00:00:00

  • Breaking news on fragile sites in cancer.

    abstract::Chromosome rearrangements in B lymphocytes can be initiated by AID-associated double strand breaks (DSBs), with others arising by unclear mechanisms. A recent study by Barlow and colleagues in Cell reports on genomic regions, termed early replicating fragile sites, that may explain many AID-independent DSBs and create...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2013.01.017

    authors: Glover TW,Wilson TE

    更新日期:2013-02-11 00:00:00

  • Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.

    abstract::Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.10.008

    authors: Zhao W,Li J,Chen MM,Luo Y,Ju Z,Nesser NK,Johnson-Camacho K,Boniface CT,Lawrence Y,Pande NT,Davies MA,Herlyn M,Muranen T,Zervantonakis IK,von Euw E,Schultz A,Kumar SV,Korkut A,Spellman PT,Akbani R,Slamon DJ,Gray

    更新日期:2020-12-14 00:00:00

  • Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms.

    abstract::Overexpression of Bcl-xL, loss of p19 ARF, and loss of p53 all accelerate Myc oncogenesis. All three lesions are implicated in suppressing Myc-induced apoptosis, suggesting that this is a common mechanism by which they synergize with Myc. However, using an acutely switchable model of Myc-induced tumorigenesis, we demo...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.06.017

    authors: Finch A,Prescott J,Shchors K,Hunt A,Soucek L,Dansen TB,Swigart LB,Evan GI

    更新日期:2006-08-01 00:00:00

  • Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.

    abstract::ARID1A encodes an SWI/SNF chromatin-remodeling factor and is frequently mutated in various cancers. This study demonstrates that ARID1A-deficient cancer cells are specifically vulnerable to inhibition of the antioxidant glutathione (GSH) and the glutamate-cysteine ligase synthetase catalytic subunit (GCLC), a rate-lim...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.12.009

    authors: Ogiwara H,Takahashi K,Sasaki M,Kuroda T,Yoshida H,Watanabe R,Maruyama A,Makinoshima H,Chiwaki F,Sasaki H,Kato T,Okamoto A,Kohno T

    更新日期:2019-02-11 00:00:00

  • Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

    abstract::We show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the pre...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.11.004

    authors: Packer LM,Rana S,Hayward R,O'Hare T,Eide CA,Rebocho A,Heidorn S,Zabriskie MS,Niculescu-Duvaz I,Druker BJ,Springer C,Marais R

    更新日期:2011-12-13 00:00:00

  • The potential of new tumor endothelium-specific markers for the development of antivascular therapy.

    abstract::Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anticancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium have been identified during the last decade. However, due to the expression in both physiological and tumor angiogenesis, only a ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2007.05.004

    authors: Li JL,Harris AL

    更新日期:2007-06-01 00:00:00

  • Stressing Out about Cancer Immunotherapy.

    abstract::Stress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells-the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3-as a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccell.2019.10.013

    authors: He XY,Ng D,Van Aelst L,Egeblad M

    更新日期:2019-11-11 00:00:00

  • ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis.

    abstract::Inhibition of ERK-MAPK signaling by expression of dominant-negative MEK1 in the tumor vasculature suppresses angiogenesis and tumor growth. In an organotypic tissue culture angiogenesis assay, ERK-MAPK inhibition during the migratory phase results in loss of bipolarity, detachment, and cell death of isolated endotheli...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.12.021

    authors: Mavria G,Vercoulen Y,Yeo M,Paterson H,Karasarides M,Marais R,Bird D,Marshall CJ

    更新日期:2006-01-01 00:00:00

  • BRAF inhibitor unveils its potential against advanced melanoma.

    abstract::Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 tha...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2010.10.001

    authors: Vultur A,Villanueva J,Herlyn M

    更新日期:2010-10-19 00:00:00

  • Paradoxical Puma Prohibits Pyruvate Pumps to Prime Pathology.

    abstract::PUMA is a pro-apoptotic Bcl-2 family protein that can act as a tumor suppressor or oncogene in different cancers. In this issue, Kim et al. show that PUMA, independent of its apoptotic function, enforces glycolytic metabolism by inhibiting the transport of pyruvate into the mitochondria, promoting hepatocellular carci...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2019.01.016

    authors: Green DR

    更新日期:2019-02-11 00:00:00

  • The sum is greater than the FGFR1 partner.

    abstract::Cancer-associated chromosomal translocations create chimeric oncoproteins that contribute to aberrant growth by dominant or dominant negative mechanisms. Interestingly, genes such as MLL, RARA, and EWS are fused to multiple partners. This molecular promiscuity can provide important functional information, as specific ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(04)00060-1

    authors: Braun BS,Shannon K

    更新日期:2004-03-01 00:00:00

  • ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

    abstract::Here, we show that tumor ADORA1 deletion suppresses cell growth in human melanoma cell lines in vitro and tumor development in vivo in immune-deficient xenografts. However, this deletion induces the upregulation of PD-L1 levels, which inactivates cocultured T cells in vitro, compromises anti-tumor immunity in vivo, an...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.02.006

    authors: Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X

    更新日期:2020-03-16 00:00:00

  • Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

    abstract::We elucidated genomic and transcriptomic changes that accompany the evolution of melanoma from pre-malignant lesions by sequencing DNA and RNA from primary melanomas and their adjacent precursors, as well as matched primary tumors and regional metastases. In total, we analyzed 230 histopathologically distinct areas of...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.06.005

    authors: Shain AH,Joseph NM,Yu R,Benhamida J,Liu S,Prow T,Ruben B,North J,Pincus L,Yeh I,Judson R,Bastian BC

    更新日期:2018-07-09 00:00:00

  • Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia.

    abstract::Through in silico and other analyses, we identified FOXC1 as expressed in at least 20% of human AML cases, but not in normal hematopoietic populations. FOXC1 expression in AML was almost exclusively associated with expression of the HOXA/B locus. Functional experiments demonstrated that FOXC1 contributes to a block in...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.07.017

    authors: Somerville TD,Wiseman DH,Spencer GJ,Huang X,Lynch JT,Leong HS,Williams EL,Cheesman E,Somervaille TC

    更新日期:2015-09-14 00:00:00

  • Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.

    abstract::The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistage process characterized by an early arrest of the proerythroblast differentiation followed later on by malignant transformation. Herein, we report the presence of acquired mutations in the SCF receptor gene (Kit) in 86% of tumors isolated during...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.11.009

    authors: Kosmider O,Denis N,Lacout C,Vainchenker W,Dubreuil P,Moreau-Gachelin F

    更新日期:2005-12-01 00:00:00

  • Calcification of multipotent prostate tumor endothelium.

    abstract::Solid tumors require new blood vessels for growth and metastasis, yet the biology of tumor-specific endothelial cells is poorly understood. We have isolated tumor endothelial cells from mice that spontaneously develop prostate tumors. Clonal populations of tumor endothelial cells expressed hematopoietic and mesenchyma...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2008.06.017

    authors: Dudley AC,Khan ZA,Shih SC,Kang SY,Zwaans BM,Bischoff J,Klagsbrun M

    更新日期:2008-09-09 00:00:00

  • The RB and p53 pathways in cancer.

    abstract::The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00102-2

    authors: Sherr CJ,McCormick F

    更新日期:2002-08-01 00:00:00

  • Successful targeting of ErbB2 receptors-is PTEN the key?

    abstract::Women with ErbB2-positive breast cancer have a poor prognosis, and frequently, chemotherapy treatment is ineffective. The ErbB2-targeted antibody trastuzumab improves survival when given with chemotherapy to patients with ErbB2-overexpressing metastatic disease, but treatment is not curative, and primary resistance is...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2004.08.001

    authors: Crowder RJ,Lombardi DP,Ellis MJ

    更新日期:2004-08-01 00:00:00

  • NAD(+) supplementation as a novel approach to cURIng HCC?

    abstract::In this issue of Cancer Cell, Tummala and colleagues demonstrate that unconventional prefoldin RPB5 interactor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD(+)) metabolism. The results suggest that ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2014.11.011

    authors: Mederacke I,Schwabe RF

    更新日期:2014-12-08 00:00:00

  • Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.

    abstract::Bladder cancer incurs a higher lifetime treatment cost than other cancers due to frequent recurrence of non-invasive disease. Improved prognostic biomarkers and localized therapy are needed for this large patient group. We defined two major genomic subtypes of primary stage Ta tumors. One of these was characterized by...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2017.08.005

    authors: Hurst CD,Alder O,Platt FM,Droop A,Stead LF,Burns JE,Burghel GJ,Jain S,Klimczak LJ,Lindsay H,Roulson JA,Taylor CF,Thygesen H,Cameron AJ,Ridley AJ,Mott HR,Gordenin DA,Knowles MA

    更新日期:2017-11-13 00:00:00

  • CHAF1B Overexpression: A Brake for the Differentiation of Leukemia Cells.

    abstract::In this issue of Cancer Cell, Volk et al. report that overexpression of CHAF1B displaces myeloid transcription factors from chromatin, and deletion of CHAF1B promotes differentiation of leukemia cells and suppresses leukemogenesis in a murine model, revealing a causal role of and an unexpected mechanism for CHAF1B ove...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2018.10.011

    authors: Li Q,Zhang X,Zhang Z

    更新日期:2018-11-12 00:00:00

  • Systemic spread is an early step in breast cancer.

    abstract::It is widely accepted that metastasis is a late event in cancer progression. Here, however, we show that tumor cells can disseminate systemically from earliest epithelial alterations in HER-2 and PyMT transgenic mice and from ductal carcinoma in situ in women. Wild-type mice transplanted with single premalignant HER-2...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2007.12.003

    authors: Hüsemann Y,Geigl JB,Schubert F,Musiani P,Meyer M,Burghart E,Forni G,Eils R,Fehm T,Riethmüller G,Klein CA

    更新日期:2008-01-01 00:00:00

  • Cancer's sweet tooth.

    abstract::Even in the presence of an adequate oxygen supply, many tumors metabolize the majority of the glucose they take up through glycolysis. It has been a long-held belief that this glycolytic phenotype is due to cancer-specific defects in mitochondrial oxidative phosphorylation. In this issue of Cancer Cell, Fantin et al. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2006.05.012

    authors: Bui T,Thompson CB

    更新日期:2006-06-01 00:00:00

  • Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. To investigate the cellular origin(s) of this cancer, we determined the effect of PDAC-relevant gene mutations in distinct cell types of the adult pancreas. We show that a subpopulation of Pdx1-expressing cells is susceptible to onco...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.09.027

    authors: Gidekel Friedlander SY,Chu GC,Snyder EL,Girnius N,Dibelius G,Crowley D,Vasile E,DePinho RA,Jacks T

    更新日期:2009-11-06 00:00:00

  • Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

    abstract::The recent landmark Phase III clinical trial with a VEGF-specific antibody suggests that antiangiogenic therapy must be combined with cytotoxic therapy for the treatment of solid tumors. However, there are no guidelines for optimal scheduling of these therapies. Here we show that VEGFR2 blockade creates a "normalizati...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2004.10.011

    authors: Winkler F,Kozin SV,Tong RT,Chae SS,Booth MF,Garkavtsev I,Xu L,Hicklin DJ,Fukumura D,di Tomaso E,Munn LL,Jain RK

    更新日期:2004-12-01 00:00:00

  • Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

    abstract::8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, most commonly ZNF198, to fibroblast growth factor receptor-1 (FGFR1). However, patients with BCR-FGFR1 fusion present with t...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(04)00053-4

    authors: Roumiantsev S,Krause DS,Neumann CA,Dimitri CA,Asiedu F,Cross NC,Van Etten RA

    更新日期:2004-03-01 00:00:00

  • Her 2 in 1.

    abstract::In this issue of Cancer Cell, Park et al. demonstrate that anti-erbB2 antibody primes adaptive immunity for increased tumor clearance and suggest that chemotherapy may in fact interfere with this process. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2010.07.009

    authors: Smyth MJ,Stagg J

    更新日期:2010-08-09 00:00:00

  • p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells.

    abstract::p62 is a ubiquitin-binding autophagy receptor and signaling protein that accumulates in premalignant liver diseases and most hepatocellular carcinomas (HCCs). Although p62 was proposed to participate in the formation of benign adenomas in autophagy-deficient livers, its role in HCC initiation was not explored. Here we...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2016.04.006

    authors: Umemura A,He F,Taniguchi K,Nakagawa H,Yamachika S,Font-Burgada J,Zhong Z,Subramaniam S,Raghunandan S,Duran A,Linares JF,Reina-Campos M,Umemura S,Valasek MA,Seki E,Yamaguchi K,Koike K,Itoh Y,Diaz-Meco MT,Moscat J,K

    更新日期:2016-06-13 00:00:00

  • CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance.

    abstract::The mechanisms through which tumor antigen-specific T cells are elicited in natural or chemotherapy-induced immunosurveillance have been elusive. In this issue of Cancer Cell, two papers by Broz and colleagues and Ruffell and colleagues delineate an important role for a specific dendritic cell subset characterized by ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2014.10.008

    authors: Zitvogel L,Kroemer G

    更新日期:2014-11-10 00:00:00